Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Depomed Inc    DEPO

Delayed Quote. Delayed  - 09/29 10:00:00 pm
23.89 USD   -2.61%
09/16 Depomed Receives Request to Call Special Meeting of Shareholders
09/15 EXCLUSIVE : Drugmaker Depomed prepares to explore a sale - sources
09/12 Activist Starboard demands rapid changes at Perrigo
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies 

Back to the USD 7 level

share with twitter share with LinkedIn share with facebook
share via e-mail
02/13/2013 | 03:19pm
Opinion : Bullish above USD 6.6
Target price : USD 7 Potential: 4.32%
Stop loss: USD 6.57
NASDAQ
Pharmaceuticals

From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year. In addition the publication of the third quarter of 2012 showed an incredible growth of turnover by more than 100% at USD 33.3 million compared to the same period the previous year. The growing business should allow the security to continue its ascension.

Technically, the security is in an uptrend on all time scales. Prices are coming back to the USD 6.6 short term support, level corresponding to the 20-day moving average. This configuration should allow the stock to bounce towards the USD 7 long term resistance, which will be the first target price.

According to both technical and fundamental elements, it seems opportune to take a long position at the current price. The bullish trend should allow the security to reach the USD 7 resistance. A stop loss will be placed under the USD 6.6 short term support to avoid a downtrend.

Depomed Inc : Back to the USD 7 level

© Zonebourse.com 2013
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Company
Manufactures and distributes pharmaceutical productsDepomed, Inc. is a pharmaceutical company, which manufactures and distributes pharmaceutical products to treat pain and other central nervous system conditions.Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA.The company... 
Sector
Pharmaceuticals
Calendar
10/28Shareholder meeting
More about the company
Advertisement
Financials ($)
Sales 2016 488 M
EBIT 2016 169 M
Net income 2016 -1,68 M
Debt 2016 514 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 35,86
EV / Sales 2016 4,14x
EV / Sales 2017 3,32x
Capitalization 1 505 M
More Financials
Chart DEPOMED INC
Duration : Period : Day
Depomed Inc Technical Analysis Chart | DEPO | US2499081048 | 4-Traders
Duration : Period : Week
Depomed Inc Technical Analysis Chart | DEPO | US2499081048 | 4-Traders
Surperformance© ratings  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
More Ratings